{"slug":"rna","tag":"rna","variants":["rna"],"description":"No description yet","count":19,"kinds":{"drug":19},"related":[{"slug":"test","tag":"test","shared":19}],"records":[{"id":"oncotype-dx-dcis","kind":"drug","name":"Oncotype DX Breast DCIS Score","route":"/drugs/oncotype-dx-dcis/","status":"established","tldr":"A tissue test for ductal carcinoma in situ, the earliest non-invasive stage of breast cancer, that estimates the chance of it coming back in the same breast to help decide whether radiotherapy is needed."},{"id":"oncotype-dx-colon","kind":"drug","name":"Oncotype DX Colon Recurrence Score","route":"/drugs/oncotype-dx-colon/","status":"established","tldr":"A tissue test for stage II and some stage III colon cancers that estimates how likely the cancer is to come back after surgery."},{"id":"blueprint","kind":"drug","name":"BluePrint","route":"/drugs/blueprint/","status":"established","tldr":"An 80-gene tissue test that sorts an early breast cancer into one of three biological types, used alongside MammaPrint."},{"id":"decipher-bladder","kind":"drug","name":"Decipher Bladder","route":"/drugs/decipher-bladder/","status":"established","tldr":"A tissue test that sorts a bladder cancer into molecular types, which may help judge how it will respond to chemotherapy before surgery."},{"id":"decisiondx-melanoma","kind":"drug","name":"DecisionDx-Melanoma","route":"/drugs/decisiondx-melanoma/","status":"established","tldr":"A tissue test for stage I to III skin melanoma that measures 31 genes to estimate the chance of the melanoma spreading."},{"id":"decisiondx-um","kind":"drug","name":"DecisionDx-UM","route":"/drugs/decisiondx-um/","status":"established","tldr":"A test on a small sample of an eye melanoma that measures 15 transcripts to estimate how likely it is to spread, often to the liver."},{"id":"decisiondx-scc","kind":"drug","name":"DecisionDx-SCC","route":"/drugs/decisiondx-scc/","status":"emerging","tldr":"A tissue test for high-risk squamous cell skin cancer that measures 40 genes to estimate the chance of spread; Medicare does not cover it."},{"id":"cancertype-id","kind":"drug","name":"CancerTYPE ID","route":"/drugs/cancertype-id/","status":"established","tldr":"A tissue test for cancers whose starting point cannot be found that reads 92 genes to suggest which organ the cancer came from."},{"id":"thyroseq","kind":"drug","name":"ThyroSeq v3 Genomic Classifier","route":"/drugs/thyroseq/","status":"established","tldr":"A test on a thyroid nodule needle sample whose cells looked uncertain, reading DNA and RNA to say whether the nodule is likely to be cancer and spare some people surgery."},{"id":"thygenext-thyramir","kind":"drug","name":"ThyGeNEXT and ThyraMIR v2","route":"/drugs/thygenext-thyramir/","status":"established","tldr":"A pair of tests on a thyroid nodule needle sample, one reading DNA and RNA fusions and one reading small regulatory RNAs, to judge whether an uncertain nodule is likely to be cancer."},{"id":"tempus-xr","kind":"drug","name":"Tempus xR","route":"/drugs/tempus-xr/","status":"approved","tldr":"A tumour RNA sequencing test from Tempus, usually run with its DNA panel, that finds gene fusions DNA testing can miss."},{"id":"foundationone-rna","kind":"drug","name":"FoundationOne RNA","route":"/drugs/foundationone-rna/","status":"established","tldr":"An add-on to Foundation Medicine's tumour DNA test that reads RNA to find gene fusions, some of which DNA testing misses."},{"id":"archer-fusionplex","kind":"drug","name":"Archer FusionPlex panels","route":"/drugs/archer-fusionplex/","status":"established","tldr":"Laboratory kits that read tumour RNA to find gene fusions without needing to know the partner gene in advance; sold for research use, they are widely built into laboratories' own tests."},{"id":"exodx-prostate","kind":"drug","name":"ExoDx Prostate (IntelliScore)","route":"/drugs/exodx-prostate/","status":"established","tldr":"A urine test that reads three genes from tiny vesicles shed by the prostate to estimate the chance of a significant prostate cancer, to help decide whether a biopsy is needed."},{"id":"selectmdx","kind":"drug","name":"SelectMDx","route":"/drugs/selectmdx/","status":"established","tldr":"A urine test taken after a prostate examination that reads two genes to estimate the chance of a high-grade cancer; its maker is moving customers to its newer urine test."},{"id":"myprostatescore-2","kind":"drug","name":"MyProstateScore 2.0","route":"/drugs/myprostatescore-2/","status":"established","tldr":"A urine test that reads 18 prostate cancer genes to estimate the chance of a cancer worth treating, to help decide on a biopsy."},{"id":"progensa-pca3","kind":"drug","name":"Progensa PCA3 Assay","route":"/drugs/progensa-pca3/","status":"withdrawn","tldr":"The first urine RNA test for prostate cancer approved in the United States; its approval has since been withdrawn, though Medicare still lists it."},{"id":"xpert-bladder-cancer-monitor","kind":"drug","name":"Xpert Bladder Cancer Monitor","route":"/drugs/xpert-bladder-cancer-monitor/","status":"established","tldr":"A urine test that reads five RNA markers to check for bladder cancer coming back, and in a Danish trial halved the number of camera examinations of the bladder."},{"id":"mir-sentinel","kind":"drug","name":"miR Sentinel","route":"/drugs/mir-sentinel/","status":"emerging","tldr":"A urine test that reads small RNAs from tiny vesicles to detect prostate cancer and judge its grade, so far validated in a case-control study."}]}